The effect of a luteinizing hormone-releasing hormone antagonist on experimental endometriosis in the rat

Jones RC, R C Jones, Robert C. Jones
Acta endocrinologica · 1987 · vol. 114(3) , pp. 379–382 · doi:10.1530/acta.0.1140379 · PMID:3551430 · W1964551220
Lab / animal OA: closed CC0 ⤵ 17 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Subcutaneous administration of a luteinizing hormone-releasing hormone antagonist inhibited experimental endometriosis in rats, with significant growth reduction observed at higher doses, though explant growth resumed after treatment cessation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effect of a Salk LRH analogue (Antagonist I) on growth of endometrial explants in the intact female rat was studied. Subcutaneous injection of the analogue was begun 3 weeks after transplantation of a section of endometrium to the peritoneal wall. The animals were laparotomized and the volume of the explant (length X width X height) in mm was measured with calipers on day 1 of treatment. The animals were injected daily for 3 weeks with 50, 250 or 500 micrograms of Antagonist I at which time the animals were again laparotomized and the volume of the explant measured. Eight weeks after cessation of treatment the animals were sacrificed and the volume of the explant measured. The degree of inhibition of explant growth was directly correlated with the amount of Antagonist I administered; a significant inhibition was obtained with doses of 250 or 500 micrograms. Eight weeks after cessation of treatment all explants demonstrated renewed growth, although explants in rats which had been treated with 250 or 500 micrograms had returned to only 51 and 61% of their initial volume, respectively. The results of this study demonstrate the LRH antagonists may be useful in the treatment of endometriosis although at doses considerably higher than those of the super agonists.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Animals Animals Dose-Response Relationship, Drug Dose-Response Relationship, Drug Drug Evaluation, Preclinical Drug Evaluation, Preclinical Endometriosis Endometriosis Endometriosis Estrus Estrus Estrus Female Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (17)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:35:02.130739+00:00
License: CC0 · commercial use OK